SOFAMOR DANEK STOCK CLIMBS 49% TO 19-3/8 IN THIRD QUARTER
This article was originally published in The Gray Sheet
SOFAMOR DANEK STOCK CLIMBS 49% TO 19-3/8 IN THIRD QUARTER, reversing in part a 1994 skid which had seen the issue lose nearly 70% of its market price since January, when the stock was trading in the 30s. The issue, which suffered first and second quarter drops of 34.2% and 40.5%, respectively, was the largest percentage gainer on "The Gray Sheet" M-D-D-I Index during the third quarter.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.